 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || PF-06939999 / Pfizer
P1 data, PK/PD data, Journal, Metastases: A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations. (Pubmed Central) - May 2, 2024
P1
However, no predictive biomarker was identified. The role of PRMT5 in cancer biology is complex and requires further preclinical, mechanistic investigation to identify predictive biomarkers for patient selection.
- ||| Synthetic lethality: Select projects targeting synthetic lethality TNG908 MRTX1719 SKL27969 AMG 193 AG-270 IDE397 JNJ-64619178 PRT543 PRT811 RP-6306 GSK3326595 GSK3368715 PF-06939999 JBI-778 TNG462 ISM020 AGX323 AT101/ AT201 @JacobPlieth @evaluatepharma https://t.co/74gBPzNLcn https://t.co/5Um0uV9GAB (Twitter) - Aug 17, 2022
- |||| PF-06939999 / Pfizer
Trial termination, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 16, 2022
P1, N=56, Terminated, Sponsor: Pfizer
Completed --> Terminated; The study has been terminated based on a strategic evaluation within the current Pfizer oncology portfolio. This decision is not due to any safety concerns or requests from any regulatory authorities.
- ||| PF-06939999 / Pfizer
Trial completion, Enrollment change, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - May 31, 2022
P1, N=56, Completed, Sponsor: Pfizer
This decision is not due to any safety concerns or requests from any regulatory authorities. Active, not recruiting --> Completed | N=43 --> 56
- | PF-06939999 / Pfizer
Journal: SAM Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. (Pubmed Central) - Mar 31, 2022
Drug sensitivity to PF-06939999 in NSCLC cells associates with cancer pathways including MYC, cell cycle and spliceosome, and with mutations in splicing factors such as RBM10. Translation of efficacy in mouse tumor xenograft models with splicing mutations provides rationale for therapeutic use of PF-06939999 in the treatment of splicing dysregulated NSCLC.
- || PF-06939999 / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Jan 20, 2022
P1, N=43, Active, not recruiting, Sponsor: Pfizer
Translation of efficacy in mouse tumor xenograft models with splicing mutations provides rationale for therapeutic use of PF-06939999 in the treatment of splicing dysregulated NSCLC. Recruiting --> Active, not recruiting | N=140 --> 43 | Trial completion date: Sep 2023 --> Apr 2022
- || PF-06939999 / Pfizer
Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 8, 2021
P1, N=140, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=140 --> 43 | Trial completion date: Sep 2023 --> Apr 2022 Trial completion date: Feb 2026 --> Sep 2023 | Trial primary completion date: Aug 2024 --> Apr 2022
- || PF-06939999 / Pfizer
Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 1, 2021
P1, N=140, Recruiting, Sponsor: Pfizer
Trial completion date: Feb 2026 --> Sep 2023 | Trial primary completion date: Aug 2024 --> Apr 2022 Trial completion date: Jan 2024 --> Apr 2026 | Trial primary completion date: Jul 2022 --> Oct 2024
- || PF-06939999 / Pfizer
Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 4, 2021
P1, N=140, Recruiting, Sponsor: Pfizer
Trial completion date: Jan 2024 --> Apr 2026 | Trial primary completion date: Jul 2022 --> Oct 2024 Trial completion date: Jul 2024 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jul 2022
- PF-06939999 / Pfizer
[VIRTUAL] PF‑06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_828;
P1
Objective tumor responses were observed in pts with HNSCC and NSCLC . Analysis of archival tissue for the presence of splicing factor mutations and other potential predictive biomarkers is ongoing .
- PF-06939999 / Pfizer
[VIRTUAL] Design and synthesis of carbonucleoside inhibitors of PRMT5 for the treatment of cancer: A desymmetrization approach () - Mar 28, 2021 - Abstract #ACSSp2021ACS-Sp_6206;
Furthermore, we will describe high-throughput experimentation efforts, characterization studies, and methodology development en route to the synthesis of novel tetrahydroisoquinolines via rhodium catalyzed C-H activation. We will conclude with the discovery and profile of our clinical candidate PF-06939999.
- PF-06939999 / Pfizer
[VIRTUAL] SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance () - Mar 13, 2021 - Abstract #AACR2021AACR_4231;
Drug sensitivity associates with cancer pathways including MYC, cell cycle and splicing. Translation of efficacy in mouse tumor xenograft models with splicing mutations provides rationale for therapeutic use of PF-06939999 for treatment of splicing dysregulated NSCLC.
- || PF-06939999 / Pfizer
Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 8, 2021
P1, N=140, Recruiting, Sponsor: Pfizer
Translation of efficacy in mouse tumor xenograft models with splicing mutations provides rationale for therapeutic use of PF-06939999 for treatment of splicing dysregulated NSCLC. Trial completion date: Nov 2023 --> Jul 2024 | Trial primary completion date: May 2022 --> Jan 2023
- || PF-06939999 / Pfizer
Enrollment change, Trial completion date, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 7, 2020
P1, N=140, Recruiting, Sponsor: Pfizer
Trial completion date: Nov 2023 --> Jul 2024 | Trial primary completion date: May 2022 --> Jan 2023 N=50 --> 140 | Trial completion date: Jul 2022 --> Nov 2023
- PF-06939999 / Pfizer
PF06939999 (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_327;
- || PF-06939999 / Pfizer
Enrollment open, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 1, 2019
P1, N=50, Recruiting, Sponsor: Pfizer
N=50 --> 140 | Trial completion date: Jul 2022 --> Nov 2023 Not yet recruiting --> Recruiting
- || PF-06939999 / Pfizer
New P1 trial, Metastases: A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 26, 2019
P1, N=50, Not yet recruiting, Sponsor: Pfizer